search
Back to results

Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis (COCOON)

Primary Purpose

Peritoneal Carcinomatosis, Pseudomyxoma Peritonei, Mesothelioma Peritoneum

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Cardiac coherence
Standard care
Sponsored by
Institut du Cancer de Montpellier - Val d'Aurelle
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Peritoneal Carcinomatosis focused on measuring Colon, Rectum, Stomach, Ovary

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age over 18 years
  2. Patients with peritoneal carcinosis awaiting cytoreductive surgery
  3. Patients who scored strictly above 3 on the visual analogue anxiety scale and/or the psychological distress scale
  4. Patients with sufficient command of the French language
  5. Patient affiliated to a French social security system
  6. Patient hospitalized at the Institute of cancer of Montpellier the day before his cytoreductive surgery (at T1 = D-1)
  7. Signing of informed consent before any specific trial procedure

Exclusion Criteria:

  1. Patients who already have daily practice of cardiac coherence
  2. Presence of proven psychiatric disorders (e.g., mental retardation, psychotic disorders, learning disabilities, attention deficit/hyperactivity, bipolar disorder, etc.) other than mood disorders that are reactive to the disease experience, or receiving psychotic treatment that may impair thinking, judgment or discernment
  3. Physical or sensory inability to respond to questionnaires
  4. Patients who have had a heart transplant or bypass surgery in the Year before surgery
  5. Patient with a history of uncontrolled neurological pathology within the last 6 months before inclusion in the trial
  6. Patients with a history of psychoactive substance dependence (excluding smoking) in the last 6 months before inclusion in the trial
  7. Patients with brain metastases
  8. Known natural bradycardia 50 beats per minute
  9. Beta-blocker intake in progress (digoxin, flecaine, isoptin, cordarone, diltiazem)
  10. Ongoing cardiac arrhythmias
  11. Known severe heart failure with ventricular ejection fraction strictly Below 40 %
  12. Chronic uncontrolled pain and making it difficult to practice the technique
  13. Patient with chronic obstructive pulmonary disease
  14. Legal incapacity (patient under guardianship or curatorship)

Sites / Locations

  • ICMRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Coherence cardiac

Standard care

Arm Description

Outcomes

Primary Outcome Measures

Cardiac Coherence Program Adherence Rate
Cardiac Coherence Program Adherence Rate. Patients are considered in "success" adhere to the program) if they will perform at least 20 of the 30 sessions scheduled until surgery (minimum 1 practice per day).

Secondary Outcome Measures

Anxiety by using the visual analogue scale (VAS)
This scale measures the anxiety of patient. It's a visual analogue scale which is also known as linear analogue scale. These scales require respondents to place a mark on a line on which opposing statements or descriptions are placed at either end of a (usually) 10 cm line. The points at which respondents make their mark represent where they perceive their answer to lie in this continuum. The distance between their mark and one end (or the mid-point) of the scale is recorded. The position on the left being the absence of anxiety and the position on the right an unbearable anxiety.
Anxiety and depression by using the hospital anxiety and depression scale (HADS)
One subscale for evaluation of anxiety from 0 (lower anxiety) to 21 (higher anxiety) and the other subscale for depression from 0 (lower anxiety) to 21 (higher depression)
Psychological distress scale
This scale measures the psychological distress of the patient . Psychological distress is characterized by the presence of symptoms, most often depressive or anxious.It's a visual analogue scale which is also known as linear analogue scale. These scales require respondents to place a mark on a line on which opposing statements or descriptions are placed at either end of a line. The position of the mark on the top is the higher psychological distress and at the bottom the lower psychological distress.
Generalized anxiety by using Freeston's uncertainty tolerance scale
The scale is used to identify people with generalized anxiety disorder compared to people with other anxiety disorders or people without pathologies. Range is from 27 (lower uncertainty) to 135 (higher uncertainty)
Heart rate variability
The heart rate variability is determined by using the software EmWave Pro which measures the ratio low frequencies/high frequencies.
Quality of life by using the quality of life questionnaire score (QLQ-C30)
The EORTC QLQ-C30 uses for the questions 1 to 28 a 4-point scale. The scale scores from 1 to 4: 1 ("Not at all"), 2 ("A little"), 3 ("Quite a bit") and 4 ("Very much"). Half points are not allowed. The range is 3. For the raw score, less points are considered to have a better outcome. The EORTC QLQ-C30 uses for the questions 29 and 30 a 7-points scale. The scale scores from 1 to 7: 1 ("very poor") to 7 ("excellent"). Half points are not allowed. The range is 6. First of all, raw score has to be calculated with mean values. Afterwards linear transformation is performed to be comparable. More points are considered to have a better outcome.
Number of days of hospitalization after surgery
Pain by using the visual analogue scale (VAS)
This scale measures the pain of patient. It's a visual analogue scale which is also known as linear analogue scale. These scales require respondents to place a mark on a line on which opposing statements or descriptions are placed at either end of a (usually) 10 cm line. The points at which respondents make their mark represent where they perceive their answer to lie in this continuum. The distance between their mark and one end (or the mid-point) of the scale is recorded. The position on the left being the absence of pain and the position on the right an unbearable pain.
Concentration of salivary immunoglobulin A
Number of cardiac coherence sessions per day and by patient
Reasons of non-participation reported by patients and registered in the form of inclusion
Number of patients satisfied with the cardiac coherence program
Subjective anxiety score by using the state-trait anxiety inventory form A (STAI-Y form A) questionnaire
State anxiety reflects the current emotional state, which allows the patient's nervousness and worry to be assessed during the session. The range is from 20 (lower anxiety) to 80 (higher anxiety). The patient must answer 20 questions for each part, each answer being on a 4 point Likert scale.
Subjective anxiety score by using the state-trait anxiety inventory form B (STAI-Y form B) questionnaire
Trait anxiety reflects the usual emotional state. The range is from 20 (lower anxiety) to 80 (higher anxiety).The patient must answer 20 questions for each part, each answer being on a 4 point Likert scale
Composite anxiety symptomatology score
Score including psychological, physiological and biological variables
Feedback from the instructor and investigator
Recruitment and retention rates
Duration of cardiac coherence sessions in minutes

Full Information

First Posted
July 15, 2019
Last Updated
September 26, 2023
Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
search

1. Study Identification

Unique Protocol Identification Number
NCT04024917
Brief Title
Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis
Acronym
COCOON
Official Title
Implementation of a Cardiac Coherence Program to Reduce Anxiety in Patients With Peritoneal Carcinosis Treated by Surgery: Randomized Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 21, 2021 (Actual)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
June 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The investigator proposes to use the cardiac coherence technique to diminish anxiety before the surgery of a peritoneal carcinosis of colon or stomach or ovary and pseudomyxoma or peritoneal mesothelioma.
Detailed Description
Facing a Peritoneal Carcinomatosis (PC) diagnosis requires significant psychological adjustments that may generate major distress because of heavy care and a sometimes poor prognosis. Psychological distress, which most frequently results in emotional anxiety and depressive disorders, affects nearly 40% of patients in oncology. These disorders impair their quality of life, their health behaviours, their therapeutic alliance with caregivers, and represent a risk factor for mortality since access to care, lifestyle and therapeutic adherence differ. All learned societies (e.g., American Society of Clinical Oncology - ASCO), associations (e.g., Union for International Cancer Control (UICC), World Cancer Research Fund International - WCRF) and authorities (e.g., French National Institute of Cancer) recommend both the screening and treatment of this psychological distress. This complementary therapy should be integrated in the overall management of cancer patients, especially since anxiolytics (e.g., benzodiazepines) have shown limitations in clinical trials compared with placebo or standard care. Studies evaluating relevant psychological interventions to treat these disorders are rare. It is therefore essential to assess the feasibility and relevance of implementing a non-drug intervention known for its anxiolytic and antidepressant effects, to respond early and appropriately to the distress and anxiety of patients with PC before and after their surgery. Among the various existing non-drug interventions, a targeted cardiac coherence program seems promising. Cardiac coherence corresponds to a physiological state of balance of the autonomic nervous system obtained through precise and rigorous breathing exercises. Several pilot studies justify its interest in oncology. The main objective of this study is to evaluate adherence to a cardiac coherence program aimed at reducing anxiety in patients with PC awaiting cytoreductive surgery. The secondary objectives are to evaluate the implementation of this program in a cancer center, its adoption by the patients and the impact of this practice on their anxious symptomatology, immunological response and quality of life.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peritoneal Carcinomatosis, Pseudomyxoma Peritonei, Mesothelioma Peritoneum
Keywords
Colon, Rectum, Stomach, Ovary

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Coherence cardiac
Arm Type
Experimental
Arm Title
Standard care
Arm Type
Active Comparator
Intervention Type
Other
Intervention Name(s)
Cardiac coherence
Intervention Description
An initiation session to cardiac coherence will take place D-11 before the operation (during the surgical consultation) in order to obtain a breathing rate of 6 cycles/min via a free application (Respirelax) with listening to an audio tape. 3 cardiac coherence sessions per day of 5 min (before meals) during the 11 days preceding the operation. - The program cardiac coherence will be performed during 90 days after the surgery
Intervention Type
Other
Intervention Name(s)
Standard care
Intervention Description
Standard care
Primary Outcome Measure Information:
Title
Cardiac Coherence Program Adherence Rate
Description
Cardiac Coherence Program Adherence Rate. Patients are considered in "success" adhere to the program) if they will perform at least 20 of the 30 sessions scheduled until surgery (minimum 1 practice per day).
Time Frame
Around 10 days
Secondary Outcome Measure Information:
Title
Anxiety by using the visual analogue scale (VAS)
Description
This scale measures the anxiety of patient. It's a visual analogue scale which is also known as linear analogue scale. These scales require respondents to place a mark on a line on which opposing statements or descriptions are placed at either end of a (usually) 10 cm line. The points at which respondents make their mark represent where they perceive their answer to lie in this continuum. The distance between their mark and one end (or the mid-point) of the scale is recorded. The position on the left being the absence of anxiety and the position on the right an unbearable anxiety.
Time Frame
90 days
Title
Anxiety and depression by using the hospital anxiety and depression scale (HADS)
Description
One subscale for evaluation of anxiety from 0 (lower anxiety) to 21 (higher anxiety) and the other subscale for depression from 0 (lower anxiety) to 21 (higher depression)
Time Frame
90 days
Title
Psychological distress scale
Description
This scale measures the psychological distress of the patient . Psychological distress is characterized by the presence of symptoms, most often depressive or anxious.It's a visual analogue scale which is also known as linear analogue scale. These scales require respondents to place a mark on a line on which opposing statements or descriptions are placed at either end of a line. The position of the mark on the top is the higher psychological distress and at the bottom the lower psychological distress.
Time Frame
90 days
Title
Generalized anxiety by using Freeston's uncertainty tolerance scale
Description
The scale is used to identify people with generalized anxiety disorder compared to people with other anxiety disorders or people without pathologies. Range is from 27 (lower uncertainty) to 135 (higher uncertainty)
Time Frame
90 days
Title
Heart rate variability
Description
The heart rate variability is determined by using the software EmWave Pro which measures the ratio low frequencies/high frequencies.
Time Frame
90 days
Title
Quality of life by using the quality of life questionnaire score (QLQ-C30)
Description
The EORTC QLQ-C30 uses for the questions 1 to 28 a 4-point scale. The scale scores from 1 to 4: 1 ("Not at all"), 2 ("A little"), 3 ("Quite a bit") and 4 ("Very much"). Half points are not allowed. The range is 3. For the raw score, less points are considered to have a better outcome. The EORTC QLQ-C30 uses for the questions 29 and 30 a 7-points scale. The scale scores from 1 to 7: 1 ("very poor") to 7 ("excellent"). Half points are not allowed. The range is 6. First of all, raw score has to be calculated with mean values. Afterwards linear transformation is performed to be comparable. More points are considered to have a better outcome.
Time Frame
90 days
Title
Number of days of hospitalization after surgery
Time Frame
1 month
Title
Pain by using the visual analogue scale (VAS)
Description
This scale measures the pain of patient. It's a visual analogue scale which is also known as linear analogue scale. These scales require respondents to place a mark on a line on which opposing statements or descriptions are placed at either end of a (usually) 10 cm line. The points at which respondents make their mark represent where they perceive their answer to lie in this continuum. The distance between their mark and one end (or the mid-point) of the scale is recorded. The position on the left being the absence of pain and the position on the right an unbearable pain.
Time Frame
90 days
Title
Concentration of salivary immunoglobulin A
Time Frame
90 days
Title
Number of cardiac coherence sessions per day and by patient
Time Frame
Through the study, an average of 1 year
Title
Reasons of non-participation reported by patients and registered in the form of inclusion
Time Frame
Through study completion, an average of 1 year
Title
Number of patients satisfied with the cardiac coherence program
Time Frame
90 days
Title
Subjective anxiety score by using the state-trait anxiety inventory form A (STAI-Y form A) questionnaire
Description
State anxiety reflects the current emotional state, which allows the patient's nervousness and worry to be assessed during the session. The range is from 20 (lower anxiety) to 80 (higher anxiety). The patient must answer 20 questions for each part, each answer being on a 4 point Likert scale.
Time Frame
90 days
Title
Subjective anxiety score by using the state-trait anxiety inventory form B (STAI-Y form B) questionnaire
Description
Trait anxiety reflects the usual emotional state. The range is from 20 (lower anxiety) to 80 (higher anxiety).The patient must answer 20 questions for each part, each answer being on a 4 point Likert scale
Time Frame
90 days
Title
Composite anxiety symptomatology score
Description
Score including psychological, physiological and biological variables
Time Frame
90 days
Title
Feedback from the instructor and investigator
Time Frame
90 days
Title
Recruitment and retention rates
Time Frame
1 year
Title
Duration of cardiac coherence sessions in minutes
Time Frame
Through study completion, an average of 1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age over 18 years Patients with peritoneal carcinosis awaiting cytoreductive surgery Patients who scored strictly above 3 on the visual analogue anxiety scale and/or the psychological distress scale Patients with sufficient command of the French language Patient affiliated to a French social security system Patient hospitalized at the Institute of cancer of Montpellier the day before his cytoreductive surgery (at T1 = D-1) Signing of informed consent before any specific trial procedure Exclusion Criteria: Patients who already have daily practice of cardiac coherence Presence of proven psychiatric disorders (e.g., mental retardation, psychotic disorders, learning disabilities, attention deficit/hyperactivity, bipolar disorder, etc.) other than mood disorders that are reactive to the disease experience, or receiving psychotic treatment that may impair thinking, judgment or discernment Physical or sensory inability to respond to questionnaires Patients who have had a heart transplant or bypass surgery in the Year before surgery Patient with a history of uncontrolled neurological pathology within the last 6 months before inclusion in the trial Patients with a history of psychoactive substance dependence (excluding smoking) in the last 6 months before inclusion in the trial Patients with brain metastases Known natural bradycardia 50 beats per minute Beta-blocker intake in progress (digoxin, flecaine, isoptin, cordarone, diltiazem) Ongoing cardiac arrhythmias Known severe heart failure with ventricular ejection fraction strictly Below 40 % Chronic uncontrolled pain and making it difficult to practice the technique Patient with chronic obstructive pulmonary disease Legal incapacity (patient under guardianship or curatorship)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jean-Pierre BLEUSE, MD
Phone
4 67 61 31 02
Ext
+33
Email
DRCI-icm105@icm.unicancer.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Estelle Guerdoux-Ninot, MD
Organizational Affiliation
Institut régional du cancer de Montpellier
Official's Role
Study Chair
Facility Information:
Facility Name
ICM
City
Montpellier
State/Province
Hérault
ZIP/Postal Code
34298
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jean-Pierre Bleuse, MD
Phone
467613102
Ext
+33
Email
jean-pierre.bleuse@icm.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Estelle Guerdoux, PhD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
All data will be available after publication of the results in peer-reviewed revues, and in national and international meetings. It includes all disidentified participants' data, the study protocol, the statistical analysis plan and analytic code. The corresponding author will provide data and datasets generated and/or analyzed during the study upon reasonable request.
IPD Sharing Time Frame
Access to study data upon written detailed request sent to ICM, following publication and until 5 years after publication of summary data.
IPD Sharing Access Criteria
The data shared will be limited to that required for independent mandated verification of the published results, the applicant will need authorization from ICM for personal access, and data will only be transferred after signing of a data access agreement.
Citations:
PubMed Identifier
27638671
Citation
Dodson RM, McQuellon RP, Mogal HD, Duckworth KE, Russell GB, Votanopoulos KI, Shen P, Levine EA. Quality-of-Life Evaluation After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2016 Dec;23(Suppl 5):772-783. doi: 10.1245/s10434-016-5547-y. Epub 2016 Sep 8.
Results Reference
background
PubMed Identifier
15453627
Citation
Lloyd-Williams M, Dennis M, Taylor F. A prospective study to determine the association between physical symptoms and depression in patients with advanced cancer. Palliat Med. 2004 Sep;18(6):558-63. doi: 10.1191/0269216304pm923oa.
Results Reference
background
PubMed Identifier
20085667
Citation
Pinquart M, Duberstein PR. Depression and cancer mortality: a meta-analysis. Psychol Med. 2010 Nov;40(11):1797-810. doi: 10.1017/S0033291709992285. Epub 2010 Jan 20.
Results Reference
background
PubMed Identifier
15245638
Citation
Elkins G, Staniunas R, Rajab MH, Marcus J, Snyder T. Use of a numeric visual analog anxiety scale among patients undergoing colorectal surgery. Clin Nurs Res. 2004 Aug;13(3):237-44. doi: 10.1177/1054773803262222.
Results Reference
background
PubMed Identifier
8433390
Citation
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365.
Results Reference
background
PubMed Identifier
7826158
Citation
Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995 Jan;221(1):29-42. doi: 10.1097/00000658-199501000-00004.
Results Reference
background
PubMed Identifier
20680439
Citation
Tan G, Dao TK, Farmer L, Sutherland RJ, Gevirtz R. Heart rate variability (HRV) and posttraumatic stress disorder (PTSD): a pilot study. Appl Psychophysiol Biofeedback. 2011 Mar;36(1):27-35. doi: 10.1007/s10484-010-9141-y.
Results Reference
background
PubMed Identifier
31060655
Citation
Bartos A, Bartos D, Raluca S, Mitre C, Hadade A, Iancu I, Cioltean C, Iancu C, Militaru C, Parau A, Breazu C. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis: Our Initial Experience. Chirurgia (Bucur). 2019 Mar-Apr;114(2):222-233. doi: 10.21614/chirurgia.114.2.222.
Results Reference
background
PubMed Identifier
15273552
Citation
Glehen O, Mohamed F, Sugarbaker PH. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg. 2004 Aug;240(2):278-85. doi: 10.1097/01.sla.0000133183.15705.71.
Results Reference
background
PubMed Identifier
30132068
Citation
Piso P, Stierstorfer K, Gerken M, Klinkhammer-Schalke M. Benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with isolated peritoneal metastases from colorectal cancer. Int J Colorectal Dis. 2018 Nov;33(11):1559-1567. doi: 10.1007/s00384-018-3146-z. Epub 2018 Aug 21.
Results Reference
background
PubMed Identifier
27487625
Citation
Balaphas A, Belfontali V, Ris F, Lanitis A, Meier RP, Amram ML, Roth A, Huber O, Berney T, Morel P. [Management of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy]. Rev Med Suisse. 2016 Jun 15;12(523):1190-4. French.
Results Reference
background
PubMed Identifier
29754828
Citation
Minnella EM, Carli F. Prehabilitation and functional recovery for colorectal cancer patients. Eur J Surg Oncol. 2018 Jul;44(7):919-926. doi: 10.1016/j.ejso.2018.04.016. Epub 2018 Apr 30.
Results Reference
background
PubMed Identifier
21251875
Citation
Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, Meader N. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011 Feb;12(2):160-74. doi: 10.1016/S1470-2045(11)70002-X. Epub 2011 Jan 19.
Results Reference
background
PubMed Identifier
15162149
Citation
Carlson LE, Angen M, Cullum J, Goodey E, Koopmans J, Lamont L, MacRae JH, Martin M, Pelletier G, Robinson J, Simpson JS, Speca M, Tillotson L, Bultz BD. High levels of untreated distress and fatigue in cancer patients. Br J Cancer. 2004 Jun 14;90(12):2297-304. doi: 10.1038/sj.bjc.6601887.
Results Reference
background
PubMed Identifier
28568377
Citation
Mehnert A, Hartung TJ, Friedrich M, Vehling S, Brahler E, Harter M, Keller M, Schulz H, Wegscheider K, Weis J, Koch U, Faller H. One in two cancer patients is significantly distressed: Prevalence and indicators of distress. Psychooncology. 2018 Jan;27(1):75-82. doi: 10.1002/pon.4464. Epub 2017 Jun 16.
Results Reference
background
PubMed Identifier
26384837
Citation
Basak F, Hasbahceci M, Guner S, Sisik A, Acar A, Yucel M, Kilic A, Bas G. Prediction of anxiety and depression in general surgery inpatients: A prospective cohort study of 200 consecutive patients. Int J Surg. 2015 Nov;23(Pt A):18-22. doi: 10.1016/j.ijsu.2015.09.040. Epub 2015 Sep 16.
Results Reference
background
PubMed Identifier
23602607
Citation
Kayhan F, Cicek E, Uguz F, Karababa IF, Kucur R. Mood and anxiety disorders among inpatients of a university hospital in Turkey. Gen Hosp Psychiatry. 2013 Jul-Aug;35(4):417-22. doi: 10.1016/j.genhosppsych.2013.03.004. Epub 2013 Apr 18.
Results Reference
background
PubMed Identifier
23263699
Citation
Arrieta O, Angulo LP, Nunez-Valencia C, Dorantes-Gallareta Y, Macedo EO, Martinez-Lopez D, Alvarado S, Corona-Cruz JF, Onate-Ocana LF. Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. Ann Surg Oncol. 2013 Jun;20(6):1941-8. doi: 10.1245/s10434-012-2793-5. Epub 2012 Dec 22.
Results Reference
background
PubMed Identifier
27171174
Citation
Foster C, Haviland J, Winter J, Grimmett C, Chivers Seymour K, Batehup L, Calman L, Corner J, Din A, Fenlon D, May CM, Richardson A, Smith PW; Members of the Study Advisory Committee. Pre-Surgery Depression and Confidence to Manage Problems Predict Recovery Trajectories of Health and Wellbeing in the First Two Years following Colorectal Cancer: Results from the CREW Cohort Study. PLoS One. 2016 May 12;11(5):e0155434. doi: 10.1371/journal.pone.0155434. eCollection 2016.
Results Reference
background
PubMed Identifier
23521554
Citation
Fox JP, Philip EJ, Gross CP, Desai RA, Killelea B, Desai MM. Associations between mental health and surgical outcomes among women undergoing mastectomy for cancer. Breast J. 2013 May-Jun;19(3):276-84. doi: 10.1111/tbj.12096. Epub 2013 Mar 21.
Results Reference
background
PubMed Identifier
30128769
Citation
Wada S, Inoguchi H, Sadahiro R, Matsuoka YJ, Uchitomi Y, Sato T, Shimada K, Yoshimoto S, Daiko H, Shimizu K. Preoperative Anxiety as a Predictor of Delirium in Cancer Patients: A Prospective Observational Cohort Study. World J Surg. 2019 Jan;43(1):134-142. doi: 10.1007/s00268-018-4761-0.
Results Reference
background
PubMed Identifier
2954531
Citation
Jamison RN, Parris WC, Maxson WS. Psychological factors influencing recovery from outpatient surgery. Behav Res Ther. 1987;25(1):31-7. doi: 10.1016/0005-7967(87)90112-4. No abstract available.
Results Reference
background
PubMed Identifier
11919251
Citation
Prieto JM, Blanch J, Atala J, Carreras E, Rovira M, Cirera E, Gasto C. Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. J Clin Oncol. 2002 Apr 1;20(7):1907-17. doi: 10.1200/JCO.2002.07.101.
Results Reference
background
PubMed Identifier
6856324
Citation
Scott LE, Clum GA, Peoples JB. Preoperative predictors of postoperative pain. Pain. 1983 Mar;15(3):283-93. doi: 10.1016/0304-3959(83)90063-5.
Results Reference
background
PubMed Identifier
19399773
Citation
Kim Y, Spillers RL. Quality of life of family caregivers at 2 years after a relative's cancer diagnosis. Psychooncology. 2010 Apr;19(4):431-40. doi: 10.1002/pon.1576.
Results Reference
background
PubMed Identifier
19753617
Citation
Satin JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer. 2009 Nov 15;115(22):5349-61. doi: 10.1002/cncr.24561.
Results Reference
background
PubMed Identifier
29643929
Citation
Cossu G, Saba L, Minerba L, Mascalchi M. Colorectal Cancer Screening: The Role of Psychological, Social and Background Factors in Decision-making Process. Clin Pract Epidemiol Ment Health. 2018 Mar 21;14:63-69. doi: 10.2174/1745017901814010063. eCollection 2018.
Results Reference
background
PubMed Identifier
30231391
Citation
Smith SK, Loscalzo M, Mayer C, Rosenstein DL. Best Practices in Oncology Distress Management: Beyond the Screen. Am Soc Clin Oncol Educ Book. 2018 May 23;38:813-821. doi: 10.1200/EDBK_201307.
Results Reference
background
PubMed Identifier
23411387
Citation
Wagner LI, Spiegel D, Pearman T. Using the science of psychosocial care to implement the new american college of surgeons commission on cancer distress screening standard. J Natl Compr Canc Netw. 2013 Feb 1;11(2):214-21. doi: 10.6004/jnccn.2013.0028.
Results Reference
background
PubMed Identifier
21425386
Citation
Dolbeault S, Boistard B, Meuric J, Copel L, Bredart A. Screening for distress and supportive care needs during the initial phase of the care process: a qualitative description of a clinical pilot experiment in a French cancer center. Psychooncology. 2011 Jun;20(6):585-93. doi: 10.1002/pon.1946. Epub 2011 Mar 22.
Results Reference
background
PubMed Identifier
18501045
Citation
Dolbeault S, Bredart A, Mignot V, Hardy P, Gauvain-Piquard A, Mandereau L, Asselain B, Medioni J. Screening for psychological distress in two French cancer centers: feasibility and performance of the adapted distress thermometer. Palliat Support Care. 2008 Jun;6(2):107-17. doi: 10.1017/S1478951508000187.
Results Reference
background
PubMed Identifier
25734733
Citation
Maurice-Szamburski A, Auquier P, Viarre-Oreal V, Cuvillon P, Carles M, Ripart J, Honore S, Triglia T, Loundou A, Leone M, Bruder N; PremedX Study Investigators. Effect of sedative premedication on patient experience after general anesthesia: a randomized clinical trial. JAMA. 2015 Mar 3;313(9):916-25. doi: 10.1001/jama.2015.1108.
Results Reference
background
PubMed Identifier
17333315
Citation
Karavidas MK, Lehrer PM, Vaschillo E, Vaschillo B, Marin H, Buyske S, Malinovsky I, Radvanski D, Hassett A. Preliminary results of an open label study of heart rate variability biofeedback for the treatment of major depression. Appl Psychophysiol Biofeedback. 2007 Mar;32(1):19-30. doi: 10.1007/s10484-006-9029-z. Epub 2007 Mar 1.
Results Reference
background
PubMed Identifier
26346569
Citation
Trousselard M, Canini F, Claverie D, Cungi C, Putois B, Franck N. Cardiac Coherence Training to Reduce Anxiety in Remitted Schizophrenia, a Pilot Study. Appl Psychophysiol Biofeedback. 2016 Mar;41(1):61-9. doi: 10.1007/s10484-015-9312-y.
Results Reference
background
PubMed Identifier
24808979
Citation
Berry ME, Chapple IT, Ginsberg JP, Gleichauf KJ, Meyer JA, Nagpal ML. Non-pharmacological Intervention for Chronic Pain in Veterans: A Pilot Study of Heart Rate Variability Biofeedback. Glob Adv Health Med. 2014 Mar;3(2):28-33. doi: 10.7453/gahmj.2013.075.
Results Reference
background
PubMed Identifier
22249435
Citation
Haase O, Langelotz C, Scharfenberg M, Schwenk W, Tsilimparis N. Reduction of heart rate variability after colorectal resections. Langenbecks Arch Surg. 2012 Jun;397(5):793-9. doi: 10.1007/s00423-012-0903-2. Epub 2012 Jan 17.
Results Reference
background
PubMed Identifier
30057605
Citation
De Couck M, Caers R, Spiegel D, Gidron Y. The Role of the Vagus Nerve in Cancer Prognosis: A Systematic and a Comprehensive Review. J Oncol. 2018 Jul 2;2018:1236787. doi: 10.1155/2018/1236787. eCollection 2018.
Results Reference
background
PubMed Identifier
31313812
Citation
Chambers DA. Sharpening our focus on designing for dissemination: Lessons from the SPRINT program and potential next steps for the field. Transl Behav Med. 2020 Dec 31;10(6):1416-1418. doi: 10.1093/tbm/ibz102.
Results Reference
background
PubMed Identifier
27371105
Citation
Chambers DA, Norton WE. The Adaptome: Advancing the Science of Intervention Adaptation. Am J Prev Med. 2016 Oct;51(4 Suppl 2):S124-31. doi: 10.1016/j.amepre.2016.05.011. Epub 2016 Jun 28.
Results Reference
background
PubMed Identifier
28161527
Citation
Hijazi Y, Gondal U, Aziz O. A systematic review of prehabilitation programs in abdominal cancer surgery. Int J Surg. 2017 Mar;39:156-162. doi: 10.1016/j.ijsu.2017.01.111. Epub 2017 Feb 2.
Results Reference
background
PubMed Identifier
29661279
Citation
Abelson JS, Chait A, Shen MJ, Charlson M, Dickerman A, Yeo HL. Sources of distress among patients undergoing surgery for colorectal cancer: a qualitative study. J Surg Res. 2018 Jun;226:140-149. doi: 10.1016/j.jss.2018.01.017. Epub 2018 Feb 22.
Results Reference
background
PubMed Identifier
26903574
Citation
Low CA, Bovbjerg DH, Ahrendt S, Alhelo S, Choudry H, Holtzman M, Jones HL, Pingpank JF Jr, Ramalingam L, Zeh HJ 3rd, Zureikat AH, Bartlett DL. Depressive Symptoms in Patients Scheduled for Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery: Prospective Associations With Morbidity and Mortality. J Clin Oncol. 2016 Apr 10;34(11):1217-22. doi: 10.1200/JCO.2015.62.9683. Epub 2016 Feb 22.
Results Reference
background

Learn more about this trial

Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis

We'll reach out to this number within 24 hrs